Provectus Biopharmaceuticals, Inc.

Name: Provectus Biopharmaceuticals, Inc. standardized financial statements, quarterly
Creator: Listed

PVCTOTCCIK 315545HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2025

Operating income−$938.7k, Q2 FY2026

Net income−$982.6k, Q2 FY2026

Provectus Biopharmaceuticals, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	69.7	121	238	255	110	14.3	279	57.5	0.0	0.0	not reported	not reported
Research and development	$k	351	416	556	473	414	608	403	881	346	268	333	131
Operating income	$k	(714)	(605)	(447)	(795)	(956)	(2,335)	(1,098)	(1,801)	(1,276)	(1,120)	(1,248)	(939)
Interest expense	$k	not reported	not reported	not reported	not reported	not reported	not reported	63.7	51.4	not reported	not reported	53.0	50.3
Net income	$k	(776)	(663)	(504)	(847)	(1,014)	(2,367)	(1,140)	(1,814)	(1,311)	(1,165)	(1,290)	(983)
Diluted EPS	$ per share	0.00	not reported	0.00	0.00	0.00	not reported	0.00	0.00	0.00	not reported	0.00	0.00
Basic EPS	$ per share	0.00	not reported	0.00	0.00	0.00	not reported	0.00	0.00	0.00	not reported	0.00	0.00

Balance sheet

Cash and equivalents$1.2m, Q2 FY2026

Shareholders' equity−$6.3m, Q2 FY2026

Provectus Biopharmaceuticals, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$k	367	76.6	18.0	29.6	187	307	390	386	72.5	251	224	1,157
Current assets	$k	1,592	1,365	1,009	800	760	977	649	568	278	568	460	1,369
Total assets	$k	1,690	1,449	1,079	856	802	1,006	666	722	420	698	578	1,474
Current liabilities	$k	9,172	9,017	8,516	8,370	6,225	6,975	5,735	6,493	6,472	6,897	7,242	7,707
Total liabilities	$k	9,209	9,042	8,529	8,370	6,225	6,975	5,735	6,597	6,587	7,000	7,308	7,761
Short-term borrowings	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$k	(7,519)	(7,593)	(7,450)	(7,513)	(5,423)	(5,959)	(5,103)	(5,871)	(6,151)	(6,299)	(6,725)	(6,275)

Cash flow

Operating cash flow−$358.2k, Q2 FY2026

Provectus Biopharmaceuticals, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(769)	(561)	(1,044)	(763)	(565)	(912)	(1,093)	(523)	(840)	(870)	(358)	(358)
Capital expenditure	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)420.28m, Q2 FY2026

Provectus Biopharmaceuticals, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	419	419	419	420	420	420	420	420	420	420	420	420

Shares outstanding: 420.28m at Aug 11, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:21 ET. Listed shows no prices and gives no investment advice.